What Is KPV? Peptide Research Guide (2026 FDA Update)

When the FDA’s Pharmacy Compounding Advisory Committee met in July 2026, KPV was one of only two peptides — alongside BPC-157 — to receive a favorable vote for the 503A compounding list. That put a relatively under-the-radar tripeptide into the spotlight. Here is a research-focused overview. (Research context only; not medical or purchasing advice.)

What is KPV?

KPV is a short tripeptide (lysine–proline–valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). In preclinical research it is studied primarily for its role in inflammatory-pathway signaling. Because it is a small, well-defined sequence, identity and purity are relatively straightforward to verify by HPLC and mass spec — a point that matters given the FDA’s focus on data quality.

Why KPV is in the news

On July 23, 2026, the FDA advisory committee voted to recommend KPV for the 503A bulk compounding list — one of just two peptides to clear that day. Like BPC-157, it was a non-binding recommendation, not an approval, and it passed over the objection of FDA staff. See our breakdown of the PCAC vote and the full list of the seven peptides reviewed.

KPV research status in 2026

KPV remains a research-use-only material: it is not an FDA-approved drug and is not authorized for human use, and the compounding pathway is still advisory and pending a final FDA determination. For researchers, the requirement is unchanged — identity and purity confirmed at the batch level. KPV is available in the BPC-157 + KPV blend and the KLOW research kit, each with batch COAs.

---

Research use only. Peptides referenced are for in-vitro laboratory research only, not for human or veterinary use, diagnosis, treatment, or consumption. This is regulatory and general information, not legal, medical, or purchasing advice.

Sources: FDA Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026; RAPS and Drug Topics coverage; STAT, NPR, and Time reporting.